AXL1717 Clinical Data From Ongoing Phase I/II Study in Cancer Patients Will be Released in Connection With the ASCO Meeting in Chicago, June 2010
Development portfolio company, today announces that a submitted abstract has
been accepted to the ASCO meeting in
The abstract containing preliminary clinical data will be publicly
released on ASCO’s website, http://www.asco.org on
“We are pleased that the abstract containing a preliminary update of the
favorable clinical data has been accepted by 2010 Annual Meeting of the
American Society of Clinical Oncology”, says Johan Harmenberg, CEO Axelar AB.
About Axelar
Axelar is a Swedish biotech company founded in 2003. The company is
developing an insulin-like growth factor-1 (IGF-1) receptor inhibitor for
cancer treatment. Axelar is part of the Karolinska Development portfolio.
http://www.axelar.se
About AXL1717
Axelar’s lead compound, AXL1717, provides a novel treatment for a wide
range of cancers. AXL1717 is the first targeted oral small-molecule IGF-1
receptor inhibitor with no effect on the insulin receptor. AXL1717 is
presently undergoing Phase I/II clinical trials and the compound combines a
superior preclinical efficacy against numerous tumors with an excellent
tolerability profile. Most tumor cells are dependent on the IGF-1 receptor
signal pathway and the IGF-1 receptor is therefore regarded as an excellent
target for cancer therapy. To date, there are no IGF-1 receptor inhibitor
drugs on the market.
About Karolinska Development
Karolinska Development manages one of the largest portfolios of life
science companies in
model, the management team guides the commercialization of world class life
science innovations, helping to shape the next generation Pharma industry.
Since 2003, Karolinska Development has built a portfolio of some 40
companies; among the company’s projects 12 compounds are undergoing clinical
trials. The portfolio contains a total of 21 potential first-in-class
products. http://www.karolinskadevelopment.com
For further information, please contact:
Johan Harmenberg, CEO, Axelar AB
Phone: +46-(0)705-14-54-53, e-mail: johan.harmenberg@axelar.se
SOURCE Karolinska Development AB